Eckert & Ziegler Strahlen und Medizintechnik AI Stock Analysis
Want to see DE:EUZ full AI Analyst Report?
Eckert & Ziegler Strahlen und Medizintechnik (EUZ) AI Stock Analysis
Eckert & Ziegler Strahlen und Medizintechnik
(XETRA:EUZ)
The score is driven primarily by strong financial performance (robust profitability and a low-leverage balance sheet), partially offset by less consistent cash-flow conversion. Technicals are bullish but overbought (high RSI/Stoch), which tempers the outlook. Valuation is reasonable (P/E 17.63) with a modest dividend yield (1.43%).
Eckert & Ziegler Strahlen und Medizintechnik (EUZ) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 78.99M
- Dividend Yield
- 1.42%
- Average Volume (3M)
- 106.95K
- Price to Earnings (P/E)
- 17.8
- Beta (1Y)
- 1.31
- Revenue Growth
- 4.05%
- EPS Growth
- 36.66%
- Country
- Germany
- Employees
- 1,116
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Specialties
Eckert & Ziegler Strahlen und Medizintechnik Business Overview & Revenue Model
Company Description
Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of pro...
Eckert & Ziegler Strahlen und Medizintechnik Financial Statement Overview
Summary
Strong fundamentals overall: the income statement is solid (Score 86) with materially higher revenue over the period and healthy profitability, and the balance sheet is conservatively positioned (Score 84) with low and improving leverage plus strong ROE. The main drag is cash-flow consistency (Cash Flow Score 73), where operating cash flow trails net income in TTM and historical free cash flow has been volatile.
Income Statement
86Very PositiveBalance Sheet
84Very PositiveCash Flow
73Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 316.83M | 311.96M | 295.85M | 246.09M | 222.26M | 180.44M |
| Gross Profit | 151.69M | 147.21M | 143.16M | 116.34M | 106.78M | 91.08M |
| EBITDA | 97.82M | 92.13M | 85.43M | 59.67M | 57.90M | 56.73M |
| Net Income | 54.38M | 48.76M | 33.28M | 26.30M | 29.28M | 34.53M |
Balance Sheet | ||||||
| Total Assets | 496.57M | 485.68M | 442.40M | 439.36M | 416.84M | 347.73M |
| Cash, Cash Equivalents and Short-Term Investments | 120.88M | 128.76M | 118.36M | 68.00M | 82.70M | 95.02M |
| Total Debt | 38.67M | 44.80M | 55.34M | 56.30M | 49.59M | 26.97M |
| Total Liabilities | 211.22M | 232.25M | 217.18M | 215.27M | 203.21M | 155.20M |
| Stockholders Equity | 283.90M | 251.77M | 223.45M | 222.18M | 212.07M | 187.39M |
Cash Flow | ||||||
| Free Cash Flow | 29.76M | 34.39M | 49.38M | 21.12M | 3.17M | 5.00M |
| Operating Cash Flow | 52.58M | 60.41M | 66.57M | 46.95M | 34.30M | 33.85M |
| Investing Cash Flow | -27.69M | -25.93M | -16.59M | -42.74M | -41.04M | -23.59M |
| Financing Cash Flow | -26.09M | -21.53M | -9.99M | -9.28M | -5.71M | -6.06M |
Eckert & Ziegler Strahlen und Medizintechnik Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EUZ, the sentiment is Positive. The current price of 15.47 is above the 20-day moving average (MA) of 13.69, above the 50-day MA of 12.88, and above the 200-day MA of 14.14, indicating a bullish trend. The MACD of 0.57 indicates Negative momentum. The RSI at 81.94 is Negative, neither overbought nor oversold. The STOCH value of 89.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:EUZ.
Eckert & Ziegler Strahlen und Medizintechnik Peers Comparison
Overall Rating
DE:SHL77Outperform
DE:EUZ76.5Outperform
DE:M3V55Neutral
DE:SBS54Neutral
DE:GXI52Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | EUR 49.09B | 22.22 | 11.72% | 2.27% | 1.09% | 3.52% | |
| 77Outperform | EUR 968.02M | 17.78 | 20.26% | 1.42% | 4.05% | 36.66% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 55Neutral | EUR 37.49M | 27.11 | 7.77% | 4.61% | -6.92% | -67.82% | |
| 54Neutral | EUR 333.68M | -7.87 | -18.69% | 2.19% | ― | ― | |
| 52Neutral | EUR 1.07B | -2.67 | -32.84% | 0.13% | 8.90% | -609.05% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:EUZ | Eckert & Ziegler Strahlen und Medizintechnik | 15.47 | -0.15 | -0.93% | |
| DE:GXI | Gerresheimer AG | 31.06 | 6.50 | 26.47% | |
| DE:M3V | MeVis Medical Solutions | 20.60 | -3.30 | -13.81% | |
| DE:SBS | STRATEC Biomedical | 27.45 | 7.83 | 39.90% | |
| DE:SHL | Siemens Healthineers | 44.00 | 3.41 | 8.39% | |
| DE:MF6 | MagForce AG | ― | ― | ― |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 16, 2026
